Cybin Inc (CYBN)

[Reyeton]

Lincoln Park Capital Fund's past performance in the majority of companies that use this vulture fund show a sp decline of 38%. There are two ways to view this, though, as good or bad. Personally, I see this as an upcoming buying opportunity. Our ceo, Drysdale, seems a cut above the rest, IMO.

[psyched]

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund

https://www.businesswire.com/news/home/20230530005628/en/Cybin-Announces-US30M-Common-Stock-Purchase-Agreement-from-Lincoln-Park-Capital-Fund

[psyched]

$CYBN Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial!

https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial

[psyched]

Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Last-Subject-Dosed-in-Part-B-of-its-Phase-1-CYB004-E-Trial/default.aspx

[Reyeton]

We have a very impressive CEO:

https://milkeninstitute.org/events/a0c1u00000cf19buar/speakers/doug-drysdale

Yesterday’s Panel discussion at Milken showed how far ahead we are in the quest to revolutionize the mental health care system.

[Reyeton]

Patience is a Virtue, a very rewarding virtue for CYBN Longs, IMO.

[psyched]

Canaccord Genuity says $CYBN’s R&D event today will be pivotal for the company and it’s shareholders, $7 PT

https://canaccordgenuity.bluematrix.com/sellside/EmailDocViewer?encrypt=3f15ecfa-d7c5-4404-9d1f-7fc780d657d8&mime=pdf&co=Canaccordgenuity&id

Watch here: https://ir.cybin.com/investors/events-and-presentations/events/event-details/2023/Cybin-Virtual-RD-Day-2023-Innovating-New-Treatment-Approaches-for-Mental-Healthcare-2023-nICt-kZDwl/default.aspx

[MomsSpaghetti]

Yup taking a big position here tomorrow. Ripe!

[sagedono]

This is due for a real move up, nice slow accumulation for months on the cheap. IMO

[TheFinalCD]

CYBN .444

[psyched]

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

- Marks first ever trial to evaluate deuterated DMT in humans –

- Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods -

- CYB004 is a patented proprietary molecule protected through 2041 -

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Approval-of-First-in-Human-Dosing-of-its-Proprietary-DMT-Molecule-CYB004/default.aspx

[makinezmoney]

$CYBN: Nice day here...... now 0.49


She's rolling up here........... looks good


GO $CYBN

[glenn1919]

CYBN......................https://stockcharts.com/h-sc/ui?s=CYBN

[sweet crude]

CO passes Prop 122 legalizing psychedelics

This huge for whole industry as many more states could be set to follow.

Also keep eye on TPIA, which has major psilocybin merger onto NASDAQ about to happen

[BubbaInSC]

Sanja Gupta Explains "Psychedelic Renaissance" In America

https://www.cnn.com/videos/health/2022/11/03/psychedelic-magic-mushrooms-depression-study-gupta-cnntm-contd-vpx.cnn

A single dose of a synthetic version of the mind-altering component of magic mushrooms, psilocybin, improved depression in people with a treatment-resistant form of the disease, a new study found. CNN's Dr. Sanjay Gupta reports.

[sagedono]

Time to kick start this baby again....yawn

[StockLogistics]

.078 gap fill soon imo chart not looking good

[sagedono]

(post #144) Just saying, easy to predict this one. I think it will finish the year around 1.80- 1.88 IMO

[transmigrator]

Its the last Adelia Milestone thank god.

Cybin Announces Final Adelia Milestone Achievement
https://www.businesswire.com/news/home/20220831005212/en/Cybin-Announces-Final-Adelia-Milestone-Achievement

[StockLogistics]

Dilution incoming :

“Pursuant to the terms of the Transaction Agreement, 33,190.1 Class B common shares in the capital of the Acquiror (the "Class B Shares") shall be issued to the Adelia Shareholders, in satisfaction of the $467,982.21 (approximately US$357,894.01) due to them on meeting the relevant milestone, at an effective issue price of $14.10 per Class B Share, determined in accordance with the Transaction Agreement and applicable securities law. The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for common shares in the capital of Cybin (the "Cybin Shares") on a 10 Cybin Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. No Class B Shares were exchangeable prior to December 14, 2021, and not more than: (i) 33 1/3% of the Class B Shares will be exchangeable prior to December 14, 2022; (ii) 66 2/3% of the Class B Shares will be exchangeable prior to December 14, 2023; and (iii) thereafter, 100% of the Class B Shares will be exchangeable”

[Reyeton]

Yet a matter of time…

https://vetsolutions.org/

[glenn1919]

CYBN....................................https://stockcharts.com/h-sc/ui?s=CYBN&p=W&b=5&g=0&id=p86431144783

[BubbaInSC]

pps consolidating?

[Reyeton]

Elon Musk is on board with psychedelics medicine:

Jim Cramer
@jimcramer
·
Jun 9
Tremendous love and awe for Elon Musk out here in SF. Just awe
241
152
2,206

Doug Drysdale
@insidepharma
·
11h
Have you looked at the pharmacoeconomic potential of psychedelics to massively reduce the $2.5T cost of mental health? Wall Street is missing out.
25
34
405

Elon Musk
@elonmusk
·
7h
Psychedelics and MDMA can make a real difference to mental health, especially for extreme depression and PTSD. We should take this seriously.

[Reyeton]

Moving forward:

https://www.clinicaltrials.gov/ct2/show/NCT05385783?term=cybin&draw=2&rank=1

[sagedono]

next climb will be 1.00-1.10 range, shouldn't be to hard. Not going to stay under a buck long. IMO

[sagedono]

Shhhh! lol

Cheers

[Hunchbackgeek]

Interesting

[BubbaInSC]

folks must be disappointed on CYBN pps movement

[sagedono]

About damn time, it's been a long wait. This will be a fun one!

[Reyeton]

Got a bump up on bell ringing. Hope it continues.

[Reyeton]

We are Ringing the Opening Bell on the NYSE tomorrow!!!

https://finance.yahoo.com/news/cybin-participate-nyse-trading-bell-120000582.html

[Singhania]

Capital Gains Report Issues Psychedelic Market News Roundup
https://finance.yahoo.com/news/capital-gains-report-issues-psychedelic-100000311.html?.tsrc=fin-srch

[GREENCHIP]

Hello all! I just got alerted to this stock, I think it is a great opportunity. Very glad to be part of history. The Q2 is going to be a fun time it is going to explode. I.m just sorry that I can.t put as much into it as I would like. Going to be HUGE.$CYBN GLTYA

[BubbaInSC]

CYBN Getting No Love

[Reyeton]

From a stocktwit post:

https://charts.stocktwits.com/production/original_447402238.jpg

[BubbaInSC]

which is good....consolidating

[Investopotia]

New Cybin $CYBN CEO interview: 3 Reasons to Watch This Psychedelics Stock

[ListenToMe]

If you "Like" Cybn... "You'll "LOVE"- PSYCF

[Twothreetimes]

CYBN stuck in a pretty tight range.

[Twothreetimes]

Been watching this a while now. Why the large sells at open?

[sagedono]

Would be nice to see an active board here. It (cybn) deserves it.

[Nosnibor]

Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders:

Post published:February 9, 2022
Post category:Press Release

– Composition of matter patent strengthens proprietary position of CYB004 as a deuterated DMT compound until 2041-

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to the Company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The patent, which is expected to expire in 2041 before consideration of any patent term extensions, covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity.

CYB004 is Cybin’s lead investigational proprietary DMT compound. In preclinical studies, CYB004 has demonstrated potential efficacy at lower doses while also increasing the duration of drug effect providing a therapeutic profile that may alleviate the common negative experiences associated with classical DMT.

“From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics. We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program” said Doug Drysdale, Chief Executive Officer of Cybin. “This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.”

Cybin plans to submit a clinical trial application for a pilot study of CYB004 in the second quarter of calendar year 2022 and expects to initiate the pilot study in the third quarter of calendar year 2022.

The Company continues to pursue multiple opportunities to secure and support its patent position for research and development evaluating deuterated tryptamines for future psychedelic-based treatments for mental illnesses

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin.

[Nosnibor]

Agreed. The patent being granted is HUGE. Buying more shares before we take flight.

[sagedono]

Wonderful news! Bada Boom! This will go to new highs this year IMO.

[sagedono]

Wonderful news! Bada Boom! This will go to new highs this year IMO.

[BubbaInSC]

yep yep upward and onward!

[sagedono]

filling yesterdays gap up, looks good!

[sagedono]

Agree, I took advantage of building a nice position under 1.05. lots of afterhours trades lately, not sure what that's about but should see a nice pop soon. IMO

[BubbaInSC]

Looks Like Bottom Is In